Welcome to Pipeline Review

Generex Biotechnology, and their wholly owned subsidiary Antigen Express, are developing promising new drugs to treat diabetes, as well as synthetic peptide vaccines targeting HER2/neu cancer and pandemic flu. The flagship product for Generex is Oral-lyn buccal insulin. Antigen Express' leading vaccine is the AE37 HER2/neu synthetic peptide vaccine to prevent breast cancer recurrence. I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I am a layman and a shareholder in this company. The left side of Pipeline Review holds blogs regarding Generex and Antigen Express, while the right side offers items of due diligence mixed with my analysis which may be of interest to others seeking to learn about Generex's pipeline. If the left side only shows the latest blog, click on the word home to view them all.

Search This Blog

Tuesday, October 9, 2012

EASD 2012 Virtual Meeting, Buccal Spray Insulin in Subjects with Impaired Glucose Tolerance

Click HERE to view the virtual presentation for Oral-lyn treatment with IGT subjects given by Dr Andreea Soare from Italy's University Campus Bio Medico at the 48th EASD Annual Meeting on October 3rd, 2012 in Berlin, Germany. Currently, Oral-lyn is being reformulated by Generex to increase the potency to allow most patients to be treated with just two to four sprays at mealtimes (instead of 10 to 20 used in past trials). This is a very positive report, and obviously beneficial effect would be lost six months after treatment was discontinued.